INCY · 10-Q · 2026Q3

INCYTE CORP

Filed 2026-10-29 · Other · View original filing on EDGAR

Everything INCY's SEC filings said, ranked

Ranked Events

• Research and Development ExpenseImportance 85 · Surprise 82
  Research and development expense increased to $1.792 billion in the third quarter of 2026 from $506.6 million a year earlier, and to $2.825 billion for the first nine months from $1.439 billion. The increases include…
• Novartis Royalty Litigation SettlementImportance 84 · Surprise 74
  In May 2025, Incyte and Novartis settled litigation concerning the duration of royalties owed under their Collaboration and License Agreement. Incyte paid Novartis $280.0 million to settle disputed royalties on U.S.…
• Liquidity and Cash PositionImportance 63 · Surprise 64
  At September 30, 2026, Incyte held $3.9 billion in cash, cash equivalents and marketable securities. Operating cash flow for the first nine months fell to $201.7 million from $870.2 million in 2025, primarily because…
• Revenue Performance and MixImportance 59 · Surprise 48
  Total revenue increased 14.0% to $1.557 billion in the third quarter of 2026 and 23.9% to $4.504 billion in the first nine months, compared with the same periods in 2025. Nine-month net sales rose 24.8% to $3.909…
• JAKAFI Demand and PricingImportance 54 · Surprise 40
  JAKAFI net sales increased to $826.5 million in the third quarter of 2026 from $791.1 million a year earlier. Paid demand grew 12% for the quarter and 9% for the first nine months, reflecting continued growth across…
• CMS Medicaid Rebate Litigation SettlementImportance 53 · Surprise 60
  Incyte sued CMS over its regulation defining a “line extension” under the Medicaid rebate program, arguing that it improperly treated OPZELURA as a line extension of JAKAFI. Under a second-quarter 2026 agreement, CMS…
• ATEBRIOZ Mirum Licensing DealImportance 43 · Surprise 42
  In April 2026, Incyte granted Mirum worldwide rights to ATEBRIOZ (zilurgisertib), receiving an upfront payment and eligibility for development and regulatory milestones, sales milestones and tiered royalties in the…
• Cost of Sales TrendsImportance 41 · Surprise 48
  Cost of sales increased 9.8% to $108.7 million in the third quarter of 2026 and 26.8% to $318.2 million for the first nine months, compared with 2025. Nine-month royalty expense rose to $111.2 million from $90.4…
• U.S. Tax Law ChangesImportance 40 · Surprise 42
  The One Big Beautiful Bill Act was enacted in July 2025 and modified key provisions of the 2017 Tax Cuts and Jobs Act. The change permitting expensing of domestic research costs materially reduced Incyte’s U.S. tax…
• OPZELURA Product ExpansionImportance 35 · Surprise 42
  OPZELURA (ruxolitinib) cream gained European Commission approval in July 2026 for moderate atopic dermatitis in adults for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or…
• JAKAFI XR Product LaunchImportance 35 · Surprise 42
  In May 2026, the FDA approved JAKAFI XR, an extended-release ruxolitinib tablet. It is indicated for adults with intermediate- or high-risk myelofibrosis and adults with polycythemia vera who have had an inadequate…
• OPZELURA Demand and MarketsImportance 33 · Surprise 24
  Excluding the one-time $246.0 million CMS-related sales benefit, OPZELURA’s nine-month net sales increase was driven by $141.6 million of higher volume, partly offset by an $11.2 million price decrease. U.S. patient…
• Income Tax Rate ChangesImportance 32 · Surprise 32
  Incyte recorded income tax provisions of $96.0 million for the third quarter and $302.1 million for the first nine months of 2026, compared with $58.1 million and $287.1 million in 2025. The 2026 effective tax rates…
• Medicare Drug Price NegotiationImportance 29 · Surprise 24
  The Inflation Reduction Act created a Medicare drug price negotiation selection process that could apply to ruxolitinib phosphate. Incyte states that the ORPHAN Cures Act extended the period before ruxolitinib…
• Other Oncology Product DemandImportance 22 · Surprise 24
  Increased demand for NIKTIMVO, MONJUVI/MINJUVI and ZYNYZ primarily drove higher other hematology and oncology net sales in the third quarter and first nine months of 2026. The company attributed growth to continued…
• Tafasitamab Indication ExpansionImportance 12 · Surprise 6
  MONJUVI was approved in the United States in June 2025 for adults with relapsed or refractory follicular lymphoma, in combination with rituximab and lenalidomide. MINJUVI received European Commission approval in…
• NIKTIMVO Product PositioningImportance 12 · Surprise 6
  NIKTIMVO (axatilimab-csfr) was approved in the United States in August 2024 for chronic graft-versus-host disease after failure of at least two prior systemic therapy lines in adults and pediatric patients. Incyte…

Revenue by Product (in thousands)

Revenue by Geography (in thousands)